Immuneering Corp Cash Flow Statement
IMRX|3 years of annual SEC 10-K data (FY2021-FY2023)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Immuneering Corp used $44M in operating cash flow and negative free cash flow of $45M in FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Net Income | -$50.5M | -$33.5M | -$17.0M |
| Depreciation & Amortization | $247.2K | $45.5K | $24.3K |
| Operating Cash Flow | -$44.1M | -$30.9M | -$14.6M |
| Capital Expenditures | $742.5K | $60.8K | $53.4K |
| Free Cash Flow | -$44.8M | -$30.9M | -$14.7M |
| FCF Margin | -14148.4% | -1486.2% | -634.8% |